Dimethylarginines ADMA and SDMA: The Real Water-Soluble Small Toxins?

Seminars in Nephrology

Volumn 34, Issue 2, 2014, Pages 97-105

  Schepers, Eva ^a   Speer, Timo ^b   Bode Böger, Stefanie M ^c   Fliser, Danilo ^b   Kielstein, Jan T ^d  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b SAARLAND UNIVERSITY   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic kidney disease (CKD); Dialysis; HDL; Mediator; Risk factor

Indexed keywords

6 N,N' DIMETHYLARGININE; ACETYLCYSTEINE; ENDOTHELIUM DERIVED RELAXING FACTOR; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PROTON PUMP INHIBITOR; ARGININE; BIOLOGICAL MARKER; N,N'-DIMETHYLARGININE; N,N-DIMETHYLARGININE; WATER;

ACUTE KIDNEY FAILURE; AMINO ACID BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DEATH; DISEASE COURSE; DRUG EFFECT; HEART FAILURE; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; MENTAL DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; UREMIA; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; KIDNEY DISEASES; PHYSIOLOGY;

ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; WATER;

EID: 84899119328     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.02.003     Document Type: Review

References (76)

1. Vanholder R., De Smet R., Glorieux G., Argiles A., Baurmeister U., Brunet P., et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003, 63:1934-1943.
2. Kielstein J.T., Zoccali C. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2008, 17:609-615.
3. Kakimoto Y., Akazawa S. Isolation and identification of N-G,N-G- and N-G,N[U+05F3]-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem 1970, 245:5751-5758.
4. Lee K.H., Gil H.W., Yang J.O., Lee E.Y., Hong S.Y. Sequential change of asymmetric dimethylarginine levels after initiation of peritoneal dialysis in patients with end-stage renal disease. Nephrology (Carlton) 2010, 15:639-643.
5. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
6. Leiper J.M. The DDAH-ADMA-NOS pathway. Ther Drug Monit 2005, 27:744-746.
7. Tanaka M., Sydow K., Gunawan F., Jacobi J., Tsao P.S., Robbins R.C., et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005, 112:1549-1556.
8. Jacobi J., Maas R., Cordasic N., Koch K., Schmieder R.E., Böger R.H., et al. Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am J Physiol Heart Circ Physiol 2008, 294:H1058-H1066.
9. Leiper J., Nandi M., Torondel B., Murray-Rust J., Malaki M., O'Hara B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007, 13:198-203.
10. Rodionov R.N., Murry D.J., Vaulman S.F., Stevens J.W., Lentz S.R. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem 2010, 285:5385-5391.
11. Martens-Lobenhoffer J., Rodionov R.N., Drust A., Bode-Boger S.M. Detection and quantification of alpha-keto-delta-(N(G),N(G)-dimethylguanidino)valeric acid: a metabolite of asymmetric dimethylarginine. Anal Biochem 2011, 419:234-240.
12. Kittel A., Maas R., Konig J., et al. In vivo evidence that Agxt2 can regulate plasma levels of dimethylarginines in mice. Biochem Biophys Res Commun 2013, 430:84-89.
13. Kielstein J.T., Salpeter S.R., Bode-Boeger S.M., Cooke J.P., Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant 2006, 21:2446-2451.
14. Eloot S., Schepers E., Barreto D.V., Barreto F.C., Liabeuf S., Van Biesen W., et al. Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol 2011, 6:1266-1273.
15. Kielstein J.T., Boger R.H., Bode-Boger S.M., Frölich J.C., Haller H., Ritz E., et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002, 13:170-176.
16. Caglar K., Yilmaz M.I., Sonmez A., Cakir E., Kaya A., Acikel C., et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006, 70:781-787.
17. Jacobi J., Tsao P.S. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol 2008, 28:224-237.
18. Engelberger R.P., Teta D., Henry H., et al. Haemodialysis acutely reduces the plasma levels of ADMA without reversing impaired NO-dependent vasodilation. Clin Sci (Lond) 2009, 117:293-303.
19. Eiselt J., Rajdl D., Racek J., Siroka R., Trefil L., Opatrna S. Asymmetric dimethylarginine in hemodialysis, hemodiafiltration, and peritoneal dialysis. Artif Organs 2010, 34:420-425.
20. Kielstein J.T., Boger R.H., Bode-Böger S.M., Martens-Lobenhoffer J., Lonnemann G., Frölich J.C., et al. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004, 62:295-300.
21. Rifai K., Bode-Boeger S.M., Martens-Lobenhoffer J., Ernst T., Kretschmer U., Hafer C., et al. Removal of asymmetric dimethylarginine during artificial liver support using fractionated plasma separation and adsorption. Scand J Gastroenterol 2010, 45:1110-1115.
22. Kielstein J.T., Boger R.H., Bode-Boger S.M., Schäffer J., Barbey M., Koch K.M., et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999, 10:594-600.
23. Kielstein J.T., Hesse G., Bahr M.J., Tsikas D., Terkamp C., Martens-Lobenhoffer J., et al. Procedure-related pulmonary hypertension in patients with hepatocellular carcinoma undergoing percutaneous ethanol injection--role of ethanol, hemolysis, asymmetric dimethylarginine, and the nitric oxide system. Crit Care Med 2009, 37:1483-1485.
24. Kielstein J.T., Veldink H., Martens-Lobenhoffer J., Haller H., Perthel P., Lovric S., et al. Unilateral nephrectomy causes an abrupt increase in inflammatory mediators and a simultaneous decrease in plasma ADMA: a study in living kidney donors. Am J Physiol Renal Physiol 2011, 301:F1042-F1046.
25. Tutarel O., Denecke A., Bode-Boger S.M., Martens-Lobenhoffer J., Schieffer B., Westhoff-Bleck M., et al. Symmetrical dimethylarginine outperforms CKD-EPI and MDRD-derived eGFR for the assessment of renal function in patients with adult congenital heart disease. Kidney Blood Press Res 2011, 34:41-45.
26. Kielstein J.T., Veldink H., Martens-Lobenhoffer J., Haller H., Burg M., Lorenzen J.M., et al. SDMA is an early marker of change in GFR after living-related kidney donation. Nephrol Dial Transplant 2011, 26:324-328.
27. Kielstein J.T., Fliser D., Veldink H. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance?. Semin Dial 2009, 22:346-350.
28. Anderstam B., Katzarski K., Bergstrom J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997, 8:1437-1442.
29. Koch A, Weiskirchen R, Bruensing J, et al. Regulation and prognostic relevance of symmetric dimethylarginine serum concentrations in critical illness and sepsis. Mediators Inflamm. 2013;2013:413826.
30. Kielstein J.T., Czock D., Schopke T., et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006, 34:51-56.
31. Siroen M.P., van der Sijp J.R., Teerlink T., van S.C., Nijveldt R.J., Van Leeuwen P.A. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology 2005, 41:559-565.
32. Lluch P., Mauricio M.D., Vila J.M., et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood) 2006, 231:70-75.
33. Leiper J., Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999, 43:542-548.
34. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
35. Bode-Boger S.M., Scalera F., Kielstein J.T., Martens-Lobenhoffer J., Breithardt G., Fobker M., et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006, 17:1128-1134.
36. Closs E.I., Basha F.Z., Habermeier A., Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997, 1:65-73.
37. Tojo A., Welch W.J., Bremer V., Kimoto M., Kimura K., Omata M., et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997, 52:1593-1601.
38. Schepers E., Glorieux G., Dhondt A., Leybaert L., Vanholder R. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 2009, 24:1429-1435.
39. Cohen G., Glorieux G., Thornalley P., Schepers E., Meert N., Jankowski J., et al. Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia. Nephrol Dial Transplant 2007, 22:3381-3390.
40. Schepers E., Glorieux G., Dou L., Cerini C., Gayrard N., Louvet L., et al. Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation. Blood Purif 2010, 30:277-287.
41. Himmelfarb J., Stenvinkel P., Ikizler T.A., Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002, 62:1524-1538.
42. Schepers E., Barreto D.V., Liabeuf S., Glorieux G., Eloot S., Barreto F.C., et al. Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:2374-2383.
43. Speer T., Rohrer L., Blyszczuk P., Shroff R., Kuschnerus K., Kränkel N., et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 2013, 38:754-768.
44. Veldink H., Faulhaber-Walter R., Park J.K., Martens-Lobenhoffer J., Bode-Böger S., Schuett H., et al. Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice. Nephrol Dial Transplant 2013, 28:1434-1439.
45. Goonasekera C.D., Rees D.D., Woolard P., Frend A., Shah V., Dillon M.J. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997, 15:901-909.
46. Kuo H.C., Hsu C.N., Huang C.F., Lo M.H., Chien S.J., Tain Y.L. Urinary arginine methylation index associated with ambulatory blood pressure abnormalities in children with chronic kidney disease. J Am Soc Hypertens 2012, 6:385-392.
47. Busch M., Fleck C., Wolf G., Stein G. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?. Amino Acids 2006, 30:225-232.
48. Cavalca V., Veglia F., Squellerio I., De Metrio M., Rubino M., Porro B., et al. Circulating levels of dimethylarginines, chronic kidney disease and long-term clinical outcome in non-ST-elevation myocardial infarction. PLoS One 2012, 7:e48499.
49. Meinitzer A., Kielstein J.T., Pilz S., Drechsler C., Ritz E., Boehm B.O., et al. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2011, 57:112-121.
50. Siegerink B., Maas R., Vossen C.Y., Schwedhelm E., Koenig W., Böger R., et al. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol 2013, 102:193-202.
51. Luneburg N., von Holten R.A., Topper R.F., Schwedhelm E., Maas R., Boger R.H. Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function. Clin Sci (Lond) 2012, 122:105-111.
52. Schulze F., Carter A.M., Schwedhelm E., Ajjan R., Maas R., von Holten R.A., et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010, 208:518-523.
53. Worthmann H., Chen S., Martens-Lobenhoffer J., Li N., Deb M., Tryc A.B., et al. High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke. J Atheroscler Thromb 2011, 18:753-761.
54. Tutarel O., Röntgen P., Bode-Böger S.M., Martens-Lobenhoffer J., Westhoff-Bleck M., Diller G.P., et al. Symmetrical dimethylarginine is superior to NT-proBNP for detecting systemic ventricular dysfunction in adults after atrial repair for transposition of the great arteries. Int J Cardiol 2013, 168:4415-4416.
55. Ghebremariam Y.T., Lependu P., Lee J.C., Erlanson D.A., Slaviero A., Shah N.H., et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013, 128:845-853.
56. Chirinos J.A., David R., Bralley J.A., Zea-Diaz H., Munoz-Atahualpa E., Corrales-Medina F., et al. Endogenous nitric oxide synthase inhibitors, arterial hemodynamics, and subclinical vascular disease. The PREVENCION study. Hypertension 2008, 52:1051-1059.
57. Zoccali C., Mallamaci F., Maas R., Benedetto F.A., Tripepi G., Malatino L.S., et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002, 62:339-345.
58. Thum T., Tsikas D., Stein S., Schultheiss M., Eigenthaler M., Anker S.D., et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005, 46:1693-1701.
59. Meinitzer A., Seelhorst U., Wellnitz B., Halwachs-Baumann G., Boehm B.O., Winkelmann B.R., et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007, 53:273-283.
60. Zoccali C., Bode-Boger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
61. Kielstein J.T., Impraim B., Simmel S., Bode-Böger S.M., Tsikas D., Frölich J.C., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004, 109:172-177.
62. Zoccali C. ADMA: a critical cardio-renal link in heart failure?. Eur J Clin Invest 2003, 33:361-362.
63. Hsu C.P., Lin S.J., Chung M.Y., Lu T.M. Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure. Atherosclerosis 2012, 225:504-510.
64. Wilson Tang W.H., Tong W., Shrestha K., Wang Z., Levison B.S., Delfraino B., et al. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J. 2008, 29:2506-2513.
65. Visser M., Paulus W.J., Vermeulen M.A., Richir M.C., Davids M., Wisselink W., et al. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Eur J Heart Fail 2010, 12:1274-1281.
66. Tutarel O., Denecke A., Bode-Böger S.M., Martens-Lobenhoffer J., Lovric S., Bauersachs J., et al. Asymmetrical dimethylarginine--more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease. PLoS One 2012, 7:e33795.
67. Haghikia A., Podewski E., Libhaber E., Labidi S., Fischer D., Roentgen P., et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 2013, 108:366.
68. von Leitner E.C., Klinke A., Atzler D., Slocum J.L., Lund N., Kielstein J.T., et al. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation 2011, 124:2735-2745.
69. Kielstein J.T., Suntharalingam M., Perthel R., Rong S., Martens-Lobenhoffer J., Jäger K., et al. Asymmetric dimethylarginine may mediate increased heat pain threshold in experimental chronic kidney disease. Nephrol Dial Transplant 2012, 27:899-902.
70. Stojanovic I., Djordjevic G., Pavlovic R., Djordjevic V., Pavlovic D., Cvetkovic T., et al. The importance of L-arginine metabolism modulation in diabetic patients with distal symmetric polyneuropathy. J Neurol Sci 2013, 324:40-44.
71. Abdelwhab S., Lotfy G., Abdelmaksoud S. Relation between asymmetric dimethylarginine (ADMA) and hearing loss in patients with renal impairment. Ren Fail 2008, 30:877-883.
72. McEvoy M.A., Schofield P., Smith W., Agho K., Mangoni A.A., Soiza R.L., et al. Serum methylarginines and incident depression in a cohort of older adults. J Affect Disord 2013, 151:493-499.
73. Miralbell J., Lopez-Cancio E., Lopez-Oloriz J., Arenillas J.F., Barrios M., Soriano-Raya J.J., et al. Cognitive patterns in relation to biomarkers of cerebrovascular disease and vascular risk factors. Cerebrovasc Dis 2013, 36:98-105.
74. Asif M., Soiza R.L., McEvoy M., Mangoni A.A. Asymmetric dimethylarginine: a possible link between vascular disease and dementia. Curr Alzheimer Res 2013, 10:347-356.
75. Duranton F., Cohen G., De Smet R., Rodriguez M., Jankowski J., Vanholder R., et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012, 23:1258-1270.
76. Kielstein J.T., Frolich J.C., Haller H., Fliser D. ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease?. Nephrol Dial Transplant 2001, 16:1742-1745.